Marker Therapeutics Inc (MRKR)

[Inoviorulez]

Well, of course it is. The most notable thing is that if you notice the Adjuvant data in all the blood cancer, patients saw a boost in complete response and durable responses. MultiTAA doesn't hurt patients and no side effects so it can always be added to every other therapy as a maintenance. My belief for this technology is not just the monotherapy potential alone, but the fact that I believe many big pharmaceutical companies will want to combine it their checkpoint inhibitors/CAR-T/TCS therapies as well. Possibly MultiTAA could be synergistic with many other products. Especially, since it uses the patient's immune system and no T-cell is genetically modified. I view a major M&A for Marker Therapeutics.